| Today's Big NewsJul 27, 2023 |
|
October 16-18, 2023 | Boston, MA
This event is designed to bring together leaders and executives within the biotech and life sciences industry to discuss the most pressing challenges around product development, bringing an asset to market and building successful companies in this complex landscape.
|
|
| By Nick Paul Taylor Roche’s gene therapy ambitions have taken another blow. Shortly after writing down the value of one of Spark Therapeutics’ hemophilia A candidates, the Swiss drugmaker has removed a second therapy aimed at the disease from its midphase pipeline. |
|
|
|
By James Waldron Biohaven’s attempts to redefine itself as a post-migraine company are continuing to encounter headaches, with the company expressing “deep disappointment” at the FDA’s refusal to review the brain disorder drug troriluzole. |
By Annalee Armstrong Pfizer is shuffling its research leadership team, assigning additional duties to Chief Scientific Officer Mikael Dolsten, M.D., PhD., while bidding farewell to Chief Development Officer William Pao, M.D., PhD. |
By James Waldron Merck & Co.’s next-generation pneumococcal vaccine has secured success in a pair of phase 3 trials, bringing the Big Pharma within touching distance of getting the first pneumococcal conjugate shot specifically designed for adults to market. |
By Nick Paul Taylor One of Takeda’s most promising clinical programs has flunked a midphase trial. The Japanese drugmaker previously flagged the release of phase 2 data on TAK-611 in a lysosomal storage disease as an inflection point, but the failure to hit primary and secondary goals has cast doubt over the future of the program. |
By James Waldron The failure of Mersana Therapeutics’ lead ovarian cancer drug in a phase 1/2 trial has sent the biotech into a tailspin, resulting in layoffs affecting half of employees in an effort to conserve cash where possible. |
By James Waldron Medicxi has loaded up its fourth fund with $400 million, which the European life sciences firm will use to continue its mission of supporting “asset-focused” biotechs. |
By Max Bayer Precision BioSciences' calls for partnerships to advance its off-the-shelf cell therapy pipeline have intensified following a post-phase 1 meeting with U.S. regulators. |
By Gabrielle Masson Aeglea BioTherapeutics may be turning a corner. The biotech has managed to sell off its rare metabolic disease asset—which the FDA denied approval for last year—to Immedica Pharma for $15 million cash and the potential to make up to $100 million in milestones. |
By Andrea Park Labcorp closed out the first half of the year with the spinoff of its clinical development business, which left the nest on June 30 as a standalone, publicly traded CRO dubbed Fortrea. |
By Joseph Keenan Worldwide Clinical Trials has signed a partnership with Cybin, a biopharma working on psychedelic-based treatment options for mental health issues. |
By Kevin Dunleavy In a quarter fueled by sales of Shingrix and its HIV medicines, GSK topped revenue expectations and bumped up its sales projection for the year. While the company anxiously awaits the launch this fall of RSV vaccine Arexvy, it is tamping down expectations of an immediate boom in sales for the potential blockbuster. |
By Joseph Keenan Fortrea has inked a deal with Australia’s Incannex Healthcare to manage investigative new drug clinical trials for a cannabinoid-based treatment for obstructive sleep apnea. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we take a deep dive into the OTC approval of Narcan, the opioid overdose drug. |
|
|---|
|
|
| WhitepaperLeading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
